Infinity Pharmaceuticals, Inc. INFI
Sep 29, 2023, 3:59 PM EDT
52-week range unavailable
- Market cap
- 21.13M
- Revenue (ttm)
- 2.67M
- Shares out
- 89.90M
- Forward P/E
- -0.43
- Volume
- 2.48M
- Open
- 0.016
- Previous close
- 0.008
- Day's range
- 0.0056 – 0.01115
- Beta
- 1.43
- Analysts
- Hold
- Price target
- 0.30 (+3650.0%)
- Earnings date
- Nov 13, 2023
2Y -2.6261 (-99.85%)
Key statistics
- Enterprise value
- -4.65M
- PEG ratio
- 0.00
- Price / sales
- 7.91
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 12.10%
- Free cash flow
- -24.45M
- Total cash
- 25.74M
- Total debt
- 777.00K
- Return on equity
- 0.00%
- Short % of float
- 0.97%
- 50-day average
- 0.186
- 200-day average
- 0.5024
Analyst view
Consensus: hold
- Strong buy1
- Buy0
- Hold3
- Sell0
- Strong sell0
Next earnings
Nov 13, 2023
Expected Nov 13, 2023. Consensus EPS estimate -0.12.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 9, 2023 | Mar 1, 2023 | -0.11 | — | — | — |
| Mar 28, 2023 | Dec 1, 2022 | -0.12 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -0.05 | — | — | — |
| Aug 9, 2022 | Jun 1, 2022 | -0.14 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 24, 2023 | Piper Sandler | down | Overweight | Neutral |
| Nov 16, 2022 | B. Riley Securities | down | Buy | Neutral |
| May 23, 2022 | Piper Sandler | main | — | Overweight |
| Mar 31, 2022 | Truist Securities | main | — | Buy |
| Mar 30, 2022 | Piper Sandler | main | — | Overweight |
| Oct 18, 2021 | HC Wainwright & Co. | init | — | Buy |
About Infinity Pharmaceuticals, Inc.
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- infi.com
News
Infinitum Amends Proposed Share Consolidation Ratio 
INFI DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 16 Deadline in Securities Class Action – INFI 
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm 
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm 
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm 
FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Infinity Pharmaceuticals, Inc. - INFI 
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm 
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm 
INFI IMPORTANT DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 16 Deadline in Securities Class Action - INFI
Your note
Sign in to keep a note on INFI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEIER DAVID WILLIAM | Director | Stock Award(Grant) | Jun 9, 2021 | 8,775 |
| BLOCH LAWRENCE E | President | Stock Award(Grant) | Jan 9, 2020 | 758,308 |
| BVF PARTNERS L P | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 10, 2021 | 0 |
| EVNIN ANTHONY B | Director | Stock Award(Grant) | Jun 15, 2022 | 215,403 |
| KUTOK JEFFERY | Officer | Stock Award(Grant) | Jan 9, 2020 | 88,120 |
| PELUSO STEPHANE | Officer | Sale | Aug 1, 2022 | 37,052 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 7.07% | 6,353,645 | 1.49M | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 4.44% | 3,994,874 | 938.79K | Mar 30, 2023 |
| Sphera Funds Management Ltd. | 1.64% | 1,476,000 | 346.86K | Mar 30, 2023 |
| Blackrock Inc. | 1.63% | 1,461,529 | 343.46K | Mar 30, 2023 |
| Carlson Capital. L.P. | 1.11% | 1,000,000 | 235.00K | Mar 30, 2023 |
| Geode Capital Management, LLC | 0.90% | 807,517 | 189.77K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.86% | 2,556,398 | 600.75K | Dec 30, 2022 |
| Vanguard Extended Market Index Fund | 1.41% | 1,260,434 | 296.20K | Dec 30, 2022 |
| Vanguard Explorer Fund, Inc. | 1.18% | 1,053,408 | 247.55K | Jan 30, 2023 |
| Fidelity Extended Market Index Fund | 0.54% | 478,590 | 112.47K | Feb 27, 2023 |
| Vanguard Variable Insurance Fund-Small Company Growth | 0.30% | 265,397 | 62.37K | Dec 30, 2022 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.27% | 240,000 | 56.40K | Dec 30, 2022 |